Publications

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

Download PDF
Resource: Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

.

Related Articles

Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell Immunotherapies

Link
High-Plex Assessment of Biomarkers in Tumors

Link